UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia - Summary - MDSpire

UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia

  • By

  • Madhur Varadpande

  • Simon Erridge

  • Arushika Aggarwal

  • Evonne Clarke

  • Katy McLachlan

  • Ross Coomber

  • Shelley Barnes

  • Alia Darweish Medniuk

  • Rahul Guru

  • Wendy Holden

  • Mohammed Sajad

  • Robert Searle

  • Azfer Usmani

  • Sanjay Varma

  • James J. Rucker

  • Michael Platt

  • Mikael H. Sodergren

  • December 4, 2025

  • 0 min

Share

Objective:

To assess the change in patient-reported outcome measures (PROMs), specifically [insert specific PROMs], for patients with fibromyalgia prescribed cannabis-based medicinal products (CBMPs) and to evaluate the prevalence of adverse events (AEs).

Key Findings:
  • CBMPs are associated with improvements in fibromyalgia-specific and general health measures over 12 months, with [insert quantitative data].
  • Adverse events reported were mostly mild to moderate.
Interpretation:

The findings suggest that CBMPs may provide symptomatic relief for fibromyalgia patients, although the evidence is based on observational data, which limits the strength of the conclusions.

Limitations:
  • The study relies on self-reported data, which may introduce bias.
  • The observational nature limits causal inferences.
  • The sample size may affect the generalizability of the findings.
Conclusion:

This study supports the potential benefits of CBMPs for fibromyalgia, highlighting the need for further research, particularly randomized controlled trials, to establish efficacy and safety.

Original Source(s)

UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia

  • by Madhur Varadpande, Simon Erridge, Arushika Aggarwal, Evonne Clarke, Katy McLachlan, Ross Coomber, Shelley Barnes, Alia Darweish Medniuk, Rahul Guru, Wendy Holden, Mohammed Sajad, Robert Searle, Azfer Usmani, Sanjay Varma, James J. Rucker, Michael Platt, Mikael H. Sodergren

  • December 4, 2025

Related Content

The effects of EXOPULSE Mollii Suit in patients with fibromyalgia: a double-blind randomized sham-controlled trial (EXOFIB2)

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Health Resorts as an integrated community healthcare model for fibromyalgia syndrome: a strategic SWOT analysis